



### Patient ≥18 years old

- New Diagnosis of Major Depressive Disorder (MDD) and/or Generalized Anxiety Disorder (GAD)
- Providing New Start Prescription of medication indicated for MDD and/or GAD from list (Box 1 & 2)

Patient history or pharmacist assessment does not meet any of the history listed in Box 3

Provide Patient with "MAP-AP Formal Informed Consent Form" & acquire consent to enroll into study Consent denied and/or patient does not want to participate → STOP

### Consent provided:

- Pharmacist partner to send/fax consent form to research team
- Pharmacist to send out "notification letter to physician" to participant's physician

# Patient enrolled (aka "Participant")

- Randomization: assigned unique identifier and group allocation pharmacist partner is notified
- Research team to send electronic questionnaire link (which includes unique identifier and group allocation) to participant to complete (month 0 questionnaire score)
- Participant will report month 0 questionnaire score to pharmacist participant via telephone

# Intervention Group

Repeat Questionnaire sent out electronically at month 1, 3, and 6 for participant to complete prior to pharmacy follow-up visit

## **Control Group**

Repeat Questionnaire sent out electronically at month 6 for participant to complete prior to pharmacy follow-up visit

### Box 1. List of medications (generic name) for MDD

- Bupropion
- Citalopram
- Desvenlafaxine
- Duloxetine
- Escitalopram
- Fluoxetine
- Fluvoxamine
- Mirtazapine
  Paroxetine
- Sertraline
- Venlafaxine
- Vortioxetine
- Amitriptyline and other TCAs
- Levomilnacipran
- Moclobemide
- Quetiapine
- Trazodone
- Vilazodone
- Phenelzine
- Tranylcypromine

### Box 2. List of medications (generic name) for GAD

- Duloxetine
- Escitalopram
- Paroxetine IR/CR
- Pregabalin
- Sertraline
- Venlafaxine XR
- Alprazolam
- Bromazepam
- Bupropion XL
- Buspirone
- Diazepam
- Hydroxyzine
- Imipramine
- Lorazepam
  Quetiapine IR/XR
- Citalopram
- Divalproex
- Divalproex
  Fluoxetine
- Mirtazapine
- Trazodone
- Aripiprazole
- Olanzapine
- Risperidone

### Box 3. Exclusion Criteria

- Current pregnancy
- Non-Alberta resident
- Unwilling or unable to participate in regular follow-up visits
- Unwilling to participate/sign consent form
- ≥2 suicide attempts per year
- Severe, psychotic, and catatonic depression
- Current substance abuse, intoxication, addiction or withdrawal requiring acute care management
- Patients diagnosed with comorbid anxiety disorders other than GAD, including: panic disorder, agoraphobia, specific phobia, social anxiety disorder, obsessive-compulsive disorder, posttraumatic stress disorder
- Patients diagnosed with comorbid depressive disorder other than MDD, including: depressive disorder due to another medical condition (e.g. hypothyroidism, MS, OSA, Parkinsons, stroke, TBI, Vitamin B12 insufficiency, Huntington disease, adrenal insufficiency, mononucleosis, systemic lupus erythematosus), adjustment disorder with depressed mood
- Patients diagnosed with concurrent ADHD, bipolar disorder, schizophrenia and schizoaffective disorder